Overview

PTS help our customers in developing tailored delivery technologies to solve drug delivery problems of actives via encapsulation (excipients) or conjugation (Drug Substance) modalities with simple, reproducible and scalable chemical and formulation processes.

State of the art facilities fully devoted to the GMP manufacturing of polyamino acid-based Drug Substances and Drug Product to support clinical development and commercialization.

Consistent reproducibility across the different project stages and scales. Excellent feedback from regulatory agencies on the CMC packages delivered to date from both EMA and FDA.

Our Skilled technical workforce and innovative business development team will get to a finish line faster, providing both cost-efficient and mitigated risk approach.

Team

JOSE VICENTE PONS ANDREU

CHIEF EXECUTIVE OFFICER

Engineer, Masters degree in company planning, Karlsruhe Institute of Technology, Germany. MIT EDP Education. More that 20 years of experience in backing up, growing and financing of innovative health Companies. Founder and investor of multiple Health and Genetic tech companies in Europe and USA.

VICENT J. NEBOT

CHIEF TECHNICAL OFFICER

PhD. in Chemistry (Universitat Jaume I de Castelló, Spain) specialized in supramolecular chemistry, soft materials and polypeptide-based systems. 10 years of experience in the field of nanomaterials and drug delivery systems in both industry and academic settings.

MARC MARCO

CHIEF FINANCIAL OFFICER

Economist. Degree in Administration and Business Management. Master in Management Control and Finance and Master in Spanish Taxation. More than 10 years of experience as a consultant of startups and biotechnological companies.

JOSE CONEJOS

OPERATIONS AND QUALITY DIRECTOR

Pharmacist, Master’s degree in pharmaceutical industry and in biomedical biotechnology. More than 12 years working under GMP environment, inspecting GxP quality systems, designing and commissioning GMP facilities, and internal operations related activities.

SERGIO ABAD

CMC Director

PhD in Chemistry (Universidad Politécnica de Valencia, Spain). Over 15 years experience in the development, validation and transfer of production and analytical methods for active ingredients and drug products.

DANIEL MORELLÓ

KEY CUSTOMER ACCOUNT MANAGER, DRUG SUBSTANCE PRODUCTION MANAGER

Graduated in Chemistry from University of Valencia. More than 7 years of experience in synthesis, manufacturing process development and scale-up implementation for polypeptides from R&D to GMP compliance. PhD to be defended by 2021.

JUAN J. ARROYO

KEY CUSTOMER ACCOUNT MANAGER, SMALL MOLECULE & PEPTIDE DELIVERY

PhD in Biochemistry and Biomedicine (University of Valencia, Spain, 2018). Over 9 years expertise in the development, physicochemical characterization and biological evaluation of polypeptide-based drug delivery systems. He joined the PTS’s R&D team 3 years ago and he focuses on providing customized delivery solutions from early conceptual development up to preclinical settings.

CARLES FELIP LEÓN

KEY CUSTOMER ACCOUNT MANAGER, NUCLEIC ACID & PROTEIN DELIVERY

PhD in Chemistry (University Jaume I of Castellón). Over 7 years of experience in organic, supramolecular and polymer chemistry. He joined PTS product development department 3 years ago to expand PTS IP to new horizons, providing PTS customers with unique and versatile solutions for benchmark, next generation drug delivery systems (DDS).

ANA ISABEL ARGENTE

QC MANAGER

PhD in Chemistry (University of Valencia, Spain) with specialization in Experimental techniques in Chemistry by Master´s degree. Over 5 years of experience in the development and validation of analytical methods based on nanomaterials applied to chromatography for the determination of compounds at trace levels in several matrices of environmental, industrial and clinical interest.

LAURA MORENO

QUALIFIED PERSON AND QA MANAGER

PhD in Pharmacy (Medicinal chemistry, 2013, University of Valencia, Spain). More than 8 years of experience in the pharmaceutical industry, getting specialized in the GMP Quality Assurance field, with a solid analytical chemistry and R&D background.

Advisory Board

MARIA JESUS VICENT

CO-FOUNDER, CHAIRMAN OF THE BOARD – EXPERT IN POLYMER THERAPEUTICS

She Joined the Centre for Polymer Therapeutics with Prof. R. Duncan after the award of a Marie Curie Postdoctoral Fellowship in 2002. In 2004, María joined the Centro de Investigación Príncipe Felipe (CIPF) as a research associate through a Marie Curie Reintegration contract and was promoted to her current position as head of the Polymer Therapeutics Laboratory at the CIPF in 2006. She is also the responsible of the Screening Platform and the Advanced Therapies Program Coordinator at CIPF. Her research interests focuses on the development of novel nanopharmaceuticals for different therapeutic applications and has been funded by national and European grants (several acting as coordinator including a recently awarded ERC Consolidator grant MyNano) from academia as well as industry.

JOSÉ LUIS FABREGAS

CMC ADVISOR

PhD in Chemistry (Autonomous University of Barcelona). Further a more than four decades-long career in CMC scientific and managerial functions in Almirall, S.A., which is the largest research-based pharmaceutical company in Spain and first Spanish pharmaceutical multinational firm, in last nine years he focused on specific CMC consultancy for pharma and biotech companies in Spain and abroad. In his whole professional tenure, he has been responsible for getting a large number of products approved by HHAA in global basis, thus fulfilling both regulatory and GMP international requirements. He has extensively authored and coauthored in this field (50+ peer reviewed papers and communications) and owns 12 patents.

PROF. DR. MATTHIAS BARZ

SCIENTIFIC ADVISORY BOARD MEMBER – EXPERT IN POLYPEPTIDE/POLYPEPTOID CHEMISTRY

He studied in Mainz (JGU) and South Korea (SNU) and obtained his PhD under the supervision of Prof. Rudolf Zentel (JGU, Mainz) in 2010. Afterwards he joined the labs of Maria J. Vicent (CIPF) and Tomas Kirchhausen (Harvard Medical School), before becoming an independent junior research group leader (JGU). Since 2020 he is Full Professor for Biotherapeutic Delivery (Biopharmacy) at the Leiden Academic Center for Drug Research (LACDR) and holds a secondary appointment in Mainz.

His research focusses on the development of polypept(o)ides, copolymers combining polypeptides and polypeptoids (polysarcosine), which were developed in his lab. Currently, his lab develops novel reactive copolymers, investigates the behaviors of polypept(o)ide nanoparticles in vitro and in vivo and applies functional the developed nanoparticles in cancer diagnosis, drug combination therapy, cancer immune therapy as well as vaccine development for infectious diseases. His research is funded by national and European funding agencies as well as industry.

PROF. DR. TIMOTHY J. DEMING

SCIENTIFIC ADVISORY BOARD MEMBER – EXPERT IN POLYPEPTIDE CHEMISTRY AND BIOMATERIALS

He received a B.S. in Chemistry from the University of California, Irvine in 1989, and graduated with a Ph.D. in Chemistry from the University of California, Berkeley, in 1993. After a NIH postdoctoral fellowship at the University of Massachusetts, Amherst with David Tirrell, he joined the faculty in the Materials Department at the University of California, Santa Barbara in 1995. Here he held appointments in the Materials and Chemistry Departments where he was promoted to Associate Professor in 1999 and Full Professor in 2003. His appointment is now as Distinguished Professor of Bioengineering and Chemistry and Biochemistry at the University of California Los Angeles. He served as the Chairman of the Bioengineering Department at UCLA from 2006 to 2011.

He is a leader in the fields of polypeptide synthesis, self-assembly of block copolypeptides, and use of polypeptides in biology, for which he has received awards from the National Science Foundation, the Office of Naval Research, The Arnold and Mabel Beckman Foundation, the Alfred P. Sloan Foundation, the Camille and Henry Dreyfus Foundation, the Materials Research Society, and the IUPAC Macromolecular Division. He is a Fellow of the American Institute of Medical and Biological Engineering, and recently received the Fulbright-Tocqueville Distinguished Chair Award.

Quality System

The quality area of PTS integrates two departments: Quality Assurance and Regulatory Affairs Department (QA) and the Quality Control Department (QC). PTS sets high quality requirements in order to integrate GMP, GLP and GDP quality standards.

Our analytical laboratory is staffed by highly-qualified personnel who use equipment specially focused, but not limited, to the quality control of polymers. All instruments are qualified, and the analysis validated conform to international and European standards.

Our facilities

State of the art facilities fully devoted to the GMP manufacturing of polyamino acid-based Drug Substances and Drug Product to support clinical development and commercialization.

GLP and GMP certified Quality Control laboratory.

300m2 GMP facility equipped with Pilot Kilo-labs

Devoted to the manufacturing of small batches of investigational medicinal products for preclinical and clinical trials. Special focus on polymer therapeutics, polypeptide-based materials and nanomedicines. GMP manufacture of key starting materials, Drug Substances and Drug Product liquid sterile formulations.

Physico-chemical Characterisation

We have built a collaboration framework with different research centres and industrial partners allowing us to access cutting-edge instrumentation for the physico-chemical characterization of polymers, APIs and nanomaterials.